ALFA Finder| Management target | Revenue 50.0% FY27 |
|---|
| Revenue growth | FY27 growth guided >50%; mid-term CAGR 20-25%. |
|---|---|
| Margins | Improving; driven by high-margin Ethical (76% GM) and Own-Brands. |
| Demand visibility | Strong; fueled by commercialized CDMO partnerships and new registrations. |
| Management confidence | High; citing clear momentum and structural transformation. |
Growth
Standalone Q1FY27 Revenue up 21.16% YoY to ₹186.08 Cr. Operating EBITDA surged 2.85x to ₹33.32 Cr; margins expanded 1,258 bps to 17.91%.
Outlook
Guided FY27 revenue growth over 50%. Mid-term revenue CAGR of 20-25% with 600-800 bps EBITDA margin expansion.
Risks
Regulatory compliance across 85+ countries and execution risks in scaling new CDMO partnerships.
Investor Presentation filed with BSE, NSE: INDSWFTLAB. Summary written with AI assistance from the document.
Ind-Swift Laboratories Ltd: key numbers
- Share price
- ₹361.30
- Market cap
- ₹3,142 Cr
- Revenue (annual)
- ₹649.1 Cr
- Net profit (annual)
- ₹43.12 Cr
- P/E (TTM)
- 37.6×Sector 43.7×
- Promoter holding
- 42.93%+0.00% QoQ
- FII holding
- 10.78%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ind-Swift Laboratories Ltd
All →Ind-Swift Laboratories Investor Presentation: Key Takeaways
Q2FY27 operating revenue ₹230.23 Cr, operating EBITDA ₹42.33 Cr (18.02% margin), PAT ₹31.03 Cr (13.21%) after API exit; now net debt-free FDF pure-play.
- Call
- Guides 50% growth
Ind-Swift Laboratories Other Announcement
Ind-Swift Laboratories Limited submitted its quarterly monitoring agency report for the period ended September 30, 2026. The report covers the utilization of Rs. 137.20 Crore raised via warrants.
Ind-Swift Laboratories Convertible Warrants
Ind-Swift Laboratories has fully utilized the Rs. 314.60 Crore proceeds from its preferential issue of convertible warrants. The monitoring agency CARE Ratings confirms no deviations in fund usage.
- Value
- ₹314.6 Cr
Ind-Swift Laboratories Results Update
Ind-Swift Laboratories reported Q2 FY27 revenue up 50% to ₹234.89 crore and PAT up 3.5x to ₹31.03 crore. Operating EBITDA margin rose to 18.02%.
Ind-Swift Laboratories Q2 FY27 Results: Net Profit ₹34.2 Cr, Up 327.5% YoY
Ind-Swift Laboratories Ltd reported revenue from operations of ₹240.5 Cr (+51.6% YoY) and net profit of ₹34.2 Cr (+327.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹34.2 Cr · +327.5% YoY
Ind-Swift Laboratories Board Meeting Date
Ind-Swift Laboratories Ltd. scheduled a board meeting for October 29, 2026, to consider and approve the standalone and consolidated financial results for the quarter and half-year.